DME

Latest News

May 12th 2022

What’s hot (and not) in retinal news

By Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

May 10th 2022

Phase 2 trial for DME treatment fails to meet primary endpoints

By Alex Delaney-Gesing, Senior Editor

the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice are correlated.

April 25th 2022

Risk of VA loss link found between DME eyes initially treated and observed

By Alex Delaney-Gesing, Senior Editor

April 18th 2022

Study: Effect of lockdowns on outcomes of retinal diseases treated with anti-VEGF therapy

By Lynda Charters

Genentech has commenced the Elevatum trial of Vabysmo (faricimab-svoa) in patients diagnosed with diabetic macular edema (DME) who are part of underrepresented patient populations, the company announced Thursday.

April 7th 2022

Genentech launches first retina study for underrepresented patients

By Alex Delaney-Gesing, Senior Editor

CME Content

Video

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Judy E. Kim, MD, FARVO, FASRS; Anat Loewenstein, MD, MHA; Deepak Sambhara, MD, FASRS

In-Person + Virtual Event

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

September 13, 2026

Virtual Event

EyeCon 2026

September 26, 2026

Video

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Video

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Video

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Video

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Video

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

Video

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

Video

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

Novartis receives European Commission approval for DME treatment

ByAlex Delaney-Gesing, Senior Editor,Optometry Times Staff Reports

April 1st 2022

This latest approval for Beovu (brolucizumab) 6 mg is the second indication granted by the EC, as it was first approved in 2020 for the treatment of AMD.

BREAKING: FDA approves faricimab to treat DME, wet AMD

ByOptometry Times Staff Reports

January 28th 2022

Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.

DME

Latest News

CME Content

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

EyeCon 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Novartis receives European Commission approval for DME treatment

BREAKING: FDA approves faricimab to treat DME, wet AMD

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

How Lytenava's FDA approval will impact clinical treatment of nAMD

FDA expands TearCare indication to improve meibomian gland function

Instilling safe contact lens wearing practices in patients

Bausch + Lomb advances 2 first-in-class eye health therapies

Study: Meta-analysis finds teacher-led vision screening highly specific for refractive error